Some patients with small-cell lung cancer can benefit from PARP inhibitor with immune checkpoint blockade
Among patients with extensive stage small-cell lung cancer (SCLC) that is positive for expression of the Schlafen-11 gene (SLFN11), those who received maintenance atezolizumab immunotherapy plus the PARP inhibitor talazoparib ...
Jun 5, 2023
0
2